76_CD
GlaxoSmithKline_NN
Consolidated_NN
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2002_CD
2002_CD
Merger_NN
,_,
restructuring_VBG
Business_NOMZ
and_PHC
disposal_NN
performance_NN
of_PIN
subsidiaries_NN
Statutory_NN
Notes_NN
m_FW
m_FW
m_FW
Turnover_NN
6_CD
21,212_CD
21,212_CD
Cost_NN
of_PIN
sales_NN
4,243_CD
366_CD
4,609_CD
Gross_NN
profit_NN
16,969_CD
366_CD
16,603_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
7,543_CD
498_CD
8,041_CD
Research_NN
and_PHC
development_NOMZ
expenditure_NN
2,732_CD
168_CD
2,900_CD
Trading_GER
profit_NN
6,694_CD
1,032_CD
5,662_CD
Other_JJ
operating_GER
income_NN
expense_NN
8_CD
111_CD
111_CD
Operating_GER
profit_NN
7,9_CD
6,583_CD
1,032_CD
5,551_CD
Share_NN
of_PIN
profits_NN
losses_NN
of_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
10_CD
75_CD
75_CD
profit_NN
on_PIN
disposal_NN
of_PIN
interest_NN
in_PIN
associate_JJ
31_CD
Product_NN
divestments_NOMZ
7_CD
11_CD
11_CD
Merger_NN
transaction_NOMZ
costs_NN
7_CD
profit_NN
loss_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
7_CD
10_CD
10_CD
profit_NN
before_IN
interest_NN
6,658_CD
1,011_CD
5,647_CD
Net_JJ
interest_NN
payable_JJ
11 141 141_CD
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
6,517_CD
1,011_CD
5,506_CD
Taxation_NOMZ
7,12_CD
1,760_CD
299_CD
1,461_CD
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
after_IN
taxation_NOMZ
4,757_CD
712_CD
4,045_CD
Minority_NOMZ
interests_NN
110_CD
110_CD
Preference_NN
share_NN
dividends_NN
20_CD
20_CD
Earnings_GER
profit_NN
attributable_JJ
to_PIN
shareholders_NN
13_CD
4,627_CD
712_CD
3,915_CD
Basic_JJ
earnings_GER
per_PIN
share_NN
13_CD
66.2_CD
p_NN
Adjusted_VBN
earnings_GER
per_PIN
share_NN
13_CD
78.3_CD
p_NN
Diluted_VBN
earnings_GER
per_PIN
share_NN
13_CD
66.0_CD
p_NN
profit_NN
attributable_JJ
to_PIN
shareholders_NN
3,915_CD
Dividends_NN
14_CD
2,346_CD
Retained_VBN
profit_NN
1,569_CD
All_QUAN
items_NN
dealt_VBD
with_PIN
in_PIN
arriving_VBG
at_PIN
business_NOMZ
performance_NN
operating_GER
profit_NN
relate_VPRT
to_TO
continuing_VBG
activities_NOMZ
._.
There_EX
is_VPRT
no_SYNE
difference_NN
between_PIN
the_DT
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
and_CC
the_DT
retained_VBN
profit_NN
stated_VBN [PUBV]
above_PLACE
and_CC
their_TPP3
historical_JJ
cost_NN
equivalents_NN
._.
During_PIN
2002_CD
,_,
FRS_NN
19_CD
Deferred_NN
Tax_NN
has_VPRT [PEAS]
been_VBN [BYPA]
implemented_VBN
by_PIN
the_DT
Group_NN
._.
This_DEMO
FRS_NN
requires_VPRT [SUAV]
deferred_JJ
tax_NN
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
on_PIN
a_DT
full_JJ
provision_NN
basis_NN
,_,
rather_CONJ
than_PIN
a_DT
partial_JJ
provision_NN
basis_NN
as_IN
in_PIN
2001_CD
and_CC
earlier_TIME
years_NN
._.
This_DEMO
change_NN
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
prior_JJ
year_NN
adjustment_NOMZ
and_CC
comparative_JJ
information_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
as_RB
necessary_JJ
._.
